311 related articles for article (PubMed ID: 23523056)
1. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
2. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
3. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
[TBL] [Abstract][Full Text] [Related]
6. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus for advanced renal cell carcinoma.
Bergmann L; Maute L; Guschmann M
Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
[TBL] [Abstract][Full Text] [Related]
8. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
Coinu A; Petrelli F; Barni S
Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
11. Second-line therapy for refractory renal-cell carcinoma.
Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
13. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
14. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
15. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
16. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
Kruck S; Bedke J; Kuczyk MA; Merseburger AS
Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of mTor inhibitors for renal cancer.
Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
[TBL] [Abstract][Full Text] [Related]
20. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
